FDA approves first anticoagulant for VTE in pediatric patients
On May 16, the FDA approved Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.